Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, combining deferasirox with sorafenib significantly reduced liver fibrosis and preneoplastic lesions in rats while also lessening adverse effects compared to sorafenib alone.

In this study, researchers assessed the effects of deferasirox in 85 children with ß-thalassemia in Kirkuk and reported that while 55.3% experienced a reduction in serum ferritin, 9.4% had adverse effects, indicating that deferasirox is generally well-tolerated as an iron chelator with modifiable side effects.

In this study, researchers created a hydrogel that reduces oxidative stress and releases a pro-angiogenic drug in response to enzyme activity, which accelerated healing and improved tissue regeneration in chronic diabetic wounds during in vivo experiments.

This report describes effective treatment of demodicosis in ferrets using amitraz, marking the first known cases in this species.

This study found that deslorelin implants can effectively reduce estradiol levels and support hair regrowth in neutered ferrets with hyperoestrogenism caused by nodular hyperplasia of the adrenocortex.

This review reported that 5-alpha-reductase inhibitors were effective in stabilizing disease progression or reducing the rate of progression in some cases of frontal fibrosing alopecia, though evidence on safety remains limited.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

The researchers in this study identified molecular mechanisms involved in frontal fibrosis alopecia, highlighting immune response and fatty acid metabolism, and developed a four-gene diagnostic model showing high accuracy in distinguishing affected individuals from controls.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

This study found that deferoxamine may protect against sensorineural hearing loss by reducing oxidative stress-induced hair cell death through iron chelation and activation of the Nrf2 signaling pathway in lab models.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This case report describes a patient with frontal fibrosing alopecia experiencing significant hair regrowth and reversal of cutaneous atrophy after treatment with the 5α-reductase inhibitor finasteride.

This review discusses FAERS data on 5-alpha reductase inhibitors and their potential implications for post-finasteride syndrome, but it does not report any new clinical results.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This review highlights the potential of targeting hepatic stellate cell ferroptosis as a treatment strategy for liver fibrosis, underscoring the need for further research into ferroptosis mechanisms in these cells to better understand and combat this condition.

This section presents 70 multiple choice questions designed for haematology specialist trainees, covering complex clinical cases and their likely diagnoses, adverse events, and management advice.

This article presents a collection of 70 multiple choice questions designed to assist haematology and core medical trainees with diagnostic and management skills, but it provides no new clinical findings.

This study reviewed the pharmacological properties of fesoterodine and found that its ability to effectively treat overactive bladder, especially in the elderly, is likely due to its specific properties, including its receptor affinity, blood-brain barrier penetration, metabolic conversion, and extended-release formulation.

In this retrospective study, all-female patients with iron deficiency anemia treated with ferric carboxymaltose experienced rapid symptom resolution and increased ferritine and hemoglobin levels, with some reporting manageable side effects such as rash and headache.

Oral dutasteride and topical pimecrolimus can safely and effectively treat Frontal Fibrosing Alopecia, leading to significant hair regrowth.

This review discusses trials on therapies for benign prostatic hyperplasia and reports that combination treatment is more effective than monotherapy for symptom relief and slowing disease progression in men with moderate to severe symptoms and enlarged prostate glands.

The document concludes that early diagnosis and treatment are crucial for managing skin diseases in ferrets.

This study found that deferiprone significantly reduced dermal fibrosis and skin thickness in mice with chronic kidney disease treated with Omniscan, suggesting iron's role in gadolinium chelate toxicity and nephrogenic systemic fibrosis.

In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.